As NIH funding for biomedical research has dwindled, scientists are turning to big drugmakers and disease-focused foundations, shifting the focus from basic to translational research, writes Luke Timmerman. The result could be a slew of new drugs, devices and diagnostics over the next decade, he writes. But moving too far away from basic research could bring missed opportunities for "a whole series of bigger breakthroughs that can come only from asking basic, open-ended research questions about how genes, cells, and lower organisms work," he writes.
Days of plenty are over for biomedical research
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan